Risk attribution — Justus Anderson
v1.0 · cal 2026-05-22Component breakdown showing every feature that contributed to this patient's risk score.
Computed score
100
Group J · Stage IV / progressing
Stored A–J score
94
Group J · Stage IV / progressing
Score buildup
Baseline 5 + +185 positive = 100
Demographic
Subtotal +5- +5
Age ≥ 70
Advanced age is an independent risk factor for PDAC.
Evidence: Current age 115· Threshold: 70 years
Symptom
Subtotal +27- +14
Abdominal pain at age ≥ 50
Unexplained abdominal pain in a patient over 50 warrants pancreas evaluation.
Evidence: Onset 2024-06-05· Triggers PANDA group C
- +13
Jaundice
Painless jaundice is a hallmark presentation of pancreatic head adenocarcinoma.
Evidence: Onset 2024-06-25
Comorbidity
Subtotal +26- +13
Has chronic condition(s)
Chronic disease burden warrants ongoing surveillance.
Evidence: 6 active conditions
- +13
New-onset T2DM after age 50
New-onset diabetes after 50 has 6–8× elevated PDAC risk in the year following diagnosis.
Evidence: T2DM onset at age 113· Triggers PANDA group D
Imaging
Subtotal +10- +10
MRI of abdomen on record
Imaging suggests the patient has been worked up for pancreatic concern.
Evidence: MRI on 2024-12-11
Procedure
Subtotal +42- +20
EUS performed
EUS is the highest-resolution modality for sub-cm pancreatic lesions; performance implies clinical concern.
Evidence: Endoscopic ultrasonography of pancreas on 2024-09-15· Triggers PANDA group G
- +22
Tissue diagnosis procedure
Biopsy or resection indicates definitive workup or treatment.
Evidence: EUS-guided fine needle aspiration of pancreas on 2024-09-18
Pathology
Subtotal +25- +25
Pancreatic tumor confirmed
Confirmed pancreatic malignancy is the defining factor for groups H–J.
Evidence: Malignant neoplasm of head of pancreas· Triggers PANDA group H
Treatment
Subtotal +20- +20
Active chemotherapy
Active cytotoxic therapy implies confirmed malignancy with treatment intent.
Evidence: Gemcitabine 1000 MG/M2 Injection, Nab-paclitaxel 125 MG/M2 Injection· Triggers PANDA group I
Response
Subtotal +30- +18
Disease progression documented
RECIST PD recorded — escalates urgency and changes treatment plan.
Evidence: At least one RECIST PD event in tumor_measurements· Triggers PANDA group J
- +12
Patient deceased
Score retained for cohort/historical analytics; treatment intent is post-mortem.
Evidence: Death recorded 1986-05-04
The Risk Engine computed group (J) is derived purely from the feature contributions above. The stored A–J group (J) comes from the cascade classifier in scripts/classify-risk.ts. Divergence between the two indicates a classifier rule that the scoring weights haven't captured, or vice versa — useful for calibration.